Hutton J T, Morris J L, Bush D F, Smith M E, Liss C L, Reines S
Department of Medical and Surgical Neurology, Texas Tech University Health Sciences Center, Lubbock, TX 79430.
Neurology. 1989 Nov;39(11 Suppl 2):67-72; discussion 72-3.
Controlled-release carbidopa/levodopa 50/200 (Sinemet CR) and standard carbidopa/levodopa (Sinemet 25/100) were compared in a multicenter double-blind trial involving 202 patients with advanced Parkinson's disease and motor response fluctuations. Treatment with Sinemet CR significantly reduced daily "off" time. According to both physician and patient global ratings, patients showed significant improvements with Sinemet CR compared to treatment with standard Sinemet. Patients preferred Sinemet CR treatment by a ratio of approximately 2 to 1. Daily dosing frequency was 33% less with Sinemet CR, while daily intake of levodopa required was increased by 25%. The safety profiles of the 2 formulations were similar. We conclude that Sinemet CR is superior to standard Sinemet for many patients with advanced Parkinson's disease, although it does not solve the problem of fluctuating motor performance.
在一项涉及202例晚期帕金森病且有运动反应波动的多中心双盲试验中，对控释卡比多巴/左旋多巴50/200（息宁控释片）和标准卡比多巴/左旋多巴（息宁25/100）进行了比较。使用息宁控释片治疗可显著减少每日“关”期时间。根据医生和患者的整体评分，与使用标准息宁治疗相比，患者使用息宁控释片后有显著改善。患者对息宁控释片治疗的偏好率约为2比1。息宁控释片的每日给药频率降低了33%，而左旋多巴的每日需求量增加了25%。两种制剂的安全性相似。我们得出结论，对于许多晚期帕金森病患者，息宁控释片优于标准息宁，尽管它不能解决运动表现波动的问题。
Zotero 插件